Encompass Health just had the kind of quarter that makes a growth strategy look bulletproof, and then immediately reminded investors why bulletproof is never quite the right word.

On August 5, the company reported second-quarter results that were strong enough to raise its full-year guidance twice in the same release: once on revenue, once on profit. Net operating revenue rose 9.6% to $1.597 billion. Adjusted earnings per share climbed 10.7% to $1.55. For the largest owner of inpatient rehabilitation hospitals in the United States, those numbers tell a story about a business that is simultaneously treating more patients, getting paid more per patient, and adding beds faster than its competitors can replicate the model.

The volume story is the real one

Encompass Health discharged 68,895 patients in the quarter, up 5.6% from a year earlier. Even stripping out the new facilities it has opened, same-store discharges still grew 2.8%, which means the growth isn't just coming from building more hospitals. Net patient revenue per discharge rose 3.9% to $22,521, so the company is collecting more money per patient on top of treating more of them.

The expansion pipeline is substantial. The company opened three hospitals totaling 139 beds in the first half of the year, added 54 beds to existing facilities, and has five more hospitals and over 100 additional beds planned before year-end.

Management lifted its full-year expectations accordingly. The company now expects revenue between $6.41 billion and $6.49 billion, and adjusted earnings per share between $6.02 and $6.25. Both ranges are higher than what the company projected just one quarter ago.

On July 23, the board also authorized up to $1 billion in stock repurchases, after the company had already bought back $145.8 million of its own shares this year. That buyback has shrunk the total share count from 102.3 million to 100.0 million, which mechanically lifts earnings per share even before any underlying profit growth. Each remaining share now claims a larger slice of a growing business.

The cost of building doesn't wait

The part of the story that deserves more attention is the cash flow line. Adjusted free cash flow actually fell 4.8% to $177.0 million in the quarter, even as operating profit grew. The reason: maintenance capital spending jumped to $66.2 million from $45.1 million a year earlier. All those new hospitals and beds require real money to build and maintain, and that spending hit the cash statement before the new revenue from those beds catches up.

Long-term debt rose to $2.598 billion from $2.447 billion at the end of 2025, after the company issued $500 million in new bonds in the first half of the year. Interest expense ticked up to $32.8 million from $30.4 million, and the quarter included a $3.2 million loss from retiring older debt early.

The buyback program is worth watching here, too. Before the board raised the ceiling to $1 billion on July 23, the company had only about $188 million remaining under its prior authorization as of June 30. That means repurchases were close to running out right at the moment the company needed the program most, to keep its per-share earnings numbers moving in the right direction.

This is the underlying tension in Encompass Health's position. Rehabilitation hospitals serve an aging population that needs exactly what the company provides: intensive, structured recovery after strokes, joint replacements, and serious injuries. That demographic demand is real and durable. But building hospitals is capital-intensive, debt-financed, and slow to generate returns. The company is betting that the long-term tailwind from an older America is large enough to absorb the near-term cost of building for it.

So far, the numbers say the bet is working. The question is whether that remains true if interest rates stay elevated, if Medicare reimbursement rates face political pressure, or if the new hospitals take longer to fill than the expansion plan assumes. None of those risks showed up in the second quarter. That doesn't mean they won't.